Deciphera Pharmaceuticals (DCPH) Tops Q2 EPS by 17c
Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q2 EPS of ($1.20), $0.17 better than the analyst estimate of ($1.37). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $890 thousand.
“The second quarter for Deciphera was a transformational one as we launched our first commercial product following the FDA approval of QINLOCK,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “We are proud to deliver QINLOCK to advanced GIST patients as the first approved therapy designed specifically for their disease. We are encouraged by the initial results from our first partial quarter of commercial sales, which speaks to both the need for a novel therapy such as QINLOCK in GIST, and our preparedness and determination in ensuring that eligible patients who can benefit from QINLOCK have access to this new treatment option.”
Mr. Hoerter continued, “Additionally, we remain focused on advancing our portfolio of innovative medicines to improve the lives of people with cancer and are pleased with the progress of our ongoing pipeline programs, DCC-3014, rebastinib and DCC-3116.”
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.